Fortis Health. Q2 FY27 Earnings Call — Analysis (NSE: FORTIS)
Fortis Healthcare and parent IHH clarified that the Delhi High Court's forensic audit order will not impede operational expansion, capex, or parent capital support.
Result quality: stable — Results context unavailable. Management sentiment: optimistic.
The take
FY26 Annual Legal Expenses ₹25 Cr .
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Annual Legal Expenses | ₹25 Cr | none · FY26 · Approximate legal expense incurred in previous year; similar budgeted for FY27 |
Guidance
IHH reaffirmed its commitment to increase its stake in Fortis to 50%-plus and fund brownfield expansion or M&A as needed.
Key themes
Forensic audit clarification and strategic continuity
Operational commentary
- Delhi High Court issued a 200-page order directing a forensic audit with a 6-month reporting timeline, covering erstwhile promoter share dissipation, IHH primary stake acquisition, RHT Health Trust asset acquisition, and role of 17 lending institutions.
- Management affirmed hospital operations, clinical quality, doctor retention, brownfield bed expansions, and M&A evaluations remain fully insulated from legal proceedings.
- IHH Healthcare confirmed that the completion of the Mandatory Open Offer (MTO) last year cleared the key regulatory hurdle, leaving it free to infuse fresh capital and evaluate merging Gleneagles assets into Fortis.
- Management and legal counsels are reviewing the Delhi High Court judgment over a 5 to 10-day window to evaluate potential legal remedies, including challenging the inclusion of primary share issuances.
Analyst Q&A
Q. What is the expected duration, worst-case outcome, and scope regarding IHH's primary investment and RHT transaction under the forensic audit?
The court set a 6-month report deadline following 4 weeks of questionnaire prep and 2 weeks of response. Management expressed surprise at the inclusion of primary share issuance and RHT transaction, reiterating full compliance and expecting no material adverse findings.
Q. Will this court order restrict IHH from infusing growth capital or pursuing the Gleneagles-Fortis integration?
IHH confirmed nothing changes post-order; Fortis remains its primary India growth engine, and IHH is fully prepared to inject capital and pursue the Gleneagles merger at the appropriate time.
Q. What are the legal options available, and will Fortis or IHH challenge the order in a higher court or initiate counter-proceedings against Daiichi Sankyo?
Legal teams are reviewing the judgment over the next 5 to 10 days to evaluate potential steps in appropriate forums, but direct counter-litigation in India is not currently planned while the matter remains sub judice.
Q. Are there any financial provisions required, and what is the ongoing run-rate for legal expenditures?
No financial liability or provisioning is required because the order is solely a fact-finding exercise; legal expenses are expected to run at roughly ₹25 Cr, consistent with the prior year.
Research and educational content only. Not investment advice.